[ad_1]
(AOF) – Insulet Corporation (+7.09% to $193.50), a US specialist in tubeless insulin pumps, took first place in the S&P 500 on Tuesday after announcing that its Omnipod 5 automated insulin delivery system is now approved for use by people with type 2 diabetes aged 18 and over in the United States. The American medtech company emphasizes that its product thus becomes the first and only insulin support system approved by the FDA for the management of type 1 and type 2 diabetes.
More than 30 million people live with type 2 diabetes in the United States, and of these, approximately 6 million people require insulin: 2.5 million of them use multiple daily injections.
Insulet recently presented data showing that Omnipod 5 significantly improves patients’ health while making their lives easier.
The Secure-T2D clinical study demonstrated that compared with previous insulin therapy methods in adults with type 2 diabetes, use of Omnipod 5 resulted in significant reductions in HbA1c, the indicator of blood sugar: 0.8% overall and 2.1% in people with a previous HbA1c of 9% or higher.
Hyperglycemia time and total daily insulin dose were also reduced. The study also demonstrated a clinically meaningful improvement in diabetes-related distress.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from sources it considers the most reliable. However, the reader remains solely responsible for their interpretation and the use of the information made available to him. Thus, the reader must hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article? Share it with your friends using the buttons below.
[ad_2]
Source link -85